Radius Health Inc.—a biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuroscience, and oncology—has promoted Kim Clarke to general counsel as the company tries to regain its footing after a recent setback.

The Boston-based company in December lost more than half of its stock market value after the transdermal patch version of its approved osteoporosis therapy, TYMLOS, flunked a Phase 3 trial. The company has since enjoyed small wins, including the nonsteroidal oral medicine elacestrant's passing a Phase 3 study for breast cancer.